Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
The 548-person U.S. study found that chronic hepatitis C infection occurred among an identical number of people who received the experimental vaccine compared to people who received a placebo.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Rectal and throat tests matter too, and providers should be recommending them.
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
These two tests make it easier to diagnose sexually transmitted infections that often go untreated.
May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.